Quantcast

Latest Percutaneous aortic valve replacement Stories

2014-09-13 12:20:33

Transcatheter Valve Durability Sustained Through Five Years WASHINGTON, Sept. 13, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement (TAVR) in patients deemed too sick for open-heart...

2014-09-09 12:29:07

STASIS Clinical Study Begins in Europe NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ -- Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe. The first STASIS case was performed by Dr....

2014-08-27 16:25:51

AUSTIN, Texas, Aug. 27, 2014 /PRNewswire/ -- On Aug. 26, 2014, physicians at Heart Hospital of Austin became the first in Texas to implant the new Portico(TM) Re-sheathable Transcatheter Aortic Valve System--an innovative, repositionable aortic heart valve and delivery system. Heart Hospital of Austin is part of the PORTICO trial, a nationwide clinical study to examine the effectiveness of the new heart valve. The Portico valve was used during a catheter-based valve replacement...

2014-08-14 12:27:46

CoreValve® System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- El Camino Hospital became one of the first hospitals in California to adopt a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery. The U.S. Food and Drug Administration (FDA) approved the Medtronic CoreValve(®) System to treat patients with...

2014-07-29 23:04:40

Global Cardiac Surgery devices market growth will be driven by extensive technological advancements, especially for transcatheter heart valve devices, reports iData Research Vancouver, BC (PRWEB) July 29, 2014 According to a new report series by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the Global Cardiac Surgery Devices Market will grow to over $8 billion by 2018. This growth will be fueled by extensive technological...

2014-07-14 23:02:06

Comprehensive study “European Market for Cardiac Surgery Devices 2014” worked out by iData Research is now available at MarketPublishers.com. According to the report, Europe’s market for cardiac surgery devices is projected to grow to over USD 3.4 billion by 2020. London, UK (PRWEB) July 14, 2014 Europe’s market for cardiac surgery devices is projected to grow to over USD 3.4 billion by 2020, with the transcatheter heart valve devices sector (composed of the transcatheter heart...

2014-07-14 20:21:24

European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus(TM) Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes. "Having the 25 mm size allows us to be more precise in selecting the...

2014-07-03 23:03:47

GIA announces the release of a comprehensive global report on Prosthetic Heart Valves. Global market for Prosthetic Heart Valves is projected to reach US$4.8 billion by 2020, driven by aging population & increasing prevalence of cardiovascular disorders, growing adoption of bioprosthetic/tissue heart valves, and regulatory clearance of Transcatheter Aortic Valve Implantation (TAVI) in major markets. San Jose, California (PRWEB) July 03, 2014 Follow us on LinkedIn. – Prosthetic heart...

2014-06-16 20:21:59

FDA Approval Includes High-Risk and Inoperable Indications, Transfemoral and Alternative Access Systems IRVINE, Calif., June 16, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received United States Food and Drug Administration (FDA) approval for its Edwards SAPIEN XT transcatheter aortic heart valve for the treatment of high-risk and inoperable patients...

2014-06-05 00:21:14

NATICK, Mass., June 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus(TM) Valve System. The RESPOND Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world. Three patients enrolled in the RESPOND Registry thus far have been successfully implanted with the Lotus Valve System. Dr. Nicolas Van Mieghem and...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related